BOSTON, Feb. 25,
2025 /PRNewswire/ -- Elevation Oncology, Inc.
(Nasdaq: ELEV), an innovative oncology company focused on the
discovery and development of selective cancer therapies to treat
patients across a range of solid tumors with significant unmet
medical needs, today announced that members of management will
participate in upcoming investor conferences in March:
- TD Cowen 45th Annual Health Care
Conference. Fireside chat on Tuesday, March 4, 2025 at 9:10 AM ET in Boston,
MA.
- Leerink Global Biopharma Conference. Fireside chat
on Tuesday, March 11, 2025 at
8:40 AM ET in Miami, FL.
A live webcast and replay of the fireside chats will be
available on the Events page of the Company's Investor Relations
website at https://investors.elevationoncology.com.
About Elevation Oncology, Inc.
Elevation Oncology is an innovative oncology company focused on
the discovery and development of selective cancer therapies to
treat patients across a range of solid tumors with significant
unmet medical needs. We are leveraging our ADC expertise to advance
a novel pipeline, initially targeting two clinically validated
targets in oncology, Claudin 18.2 and HER3. Our lead candidate,
EO-3021, is a potential best-in-class, Claudin 18.2 ADC and is
currently being evaluated in a Phase 1 trial (NCT05980416) as a
monotherapy, and in combinations with dostarlimab or ramucirumab,
in patients with advanced, unresectable or metastatic
gastric/gastroesophageal adenocarcinoma that express Claudin 18.2.
We are also advancing EO-1022, a HER3 ADC for the treatment of
patients living with solid tumors that express HER3, through
preclinical development. For more information, visit
www.ElevationOncology.com.
Elevation Oncology Investor and Media Contact
Gracie Tong
Senior Director, Investor Relations and Corporate
Communications
gtong@elevationoncology.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/elevation-oncology-to-participate-in-upcoming-investor-conferences-302382527.html
SOURCE Elevation Oncology
